title: [Management of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].
abstract: In 2016, peritoneal carcinomatosis can be considered as a chronic disease that can be treated and sometimes cured. Hyperthermic Intra PEritoneal Chemotherapy (HIPEC) is a procedure developed in the eighties. Combined with CytoReductive (CR) surgery, this protocol underwent a considerable expansion in Washington Cancer Institute. CR combined with HIPEC was demonstrated to be the only curative treatment for PseudoMyxoma Peritonei syndrome (PMP). It is actually approved in the management of peritoneal carcinomatosis of ovarian, colorectal, or peritoneal primitive (mesothelioma) origin but is still studied for gastric cancer. CR/HIPEC is associated with an important mortality and morbidity. This article takes stock of indications to CR/HIPEC.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Balaphas
authors.forename: Valentina
authors.initials: V
authors.lastname: Belfontali
authors.forename: Frédéric
authors.initials: F
authors.lastname: Ris
authors.forename: Andreas
authors.initials: A
authors.lastname: Lanitis
authors.forename: Raphael P H
authors.initials: RP
authors.lastname: Meier
authors.forename: Marie-Laure
authors.initials: ML
authors.lastname: Amram
authors.forename: Arnaud
authors.initials: A
authors.lastname: Roth
authors.forename: Olivier
authors.initials: O
authors.lastname: Huber
authors.forename: Thierry
authors.initials: T
authors.lastname: Berney
authors.forename: Philippe
authors.initials: P
authors.lastname: Morel
mesh_terms: D010478:Chemotherapy, Cancer, Regional Perfusion; D065426:Cytoreduction Surgical Procedures; D006801:Humans; D006979:Hyperthermia, Induced; D010534:Peritoneal Neoplasms / Q000628:therapy*